Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Benefit of Adding Cureety TechCare Telemonitoring to Usual Care During Injectable Anticancer Treatment: a Multicentric French Prospective Randomized Study: The OPTIMACURE Protocol

NCT06371911 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT06371911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06371911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Benefit of Adding Cureety TechCare Telemonitoring to Usual Care During Injectable Anticancer Treatment: a Multicentric French Prospective Randomized Study: The OPTIMACURE Protocol
Lead sponsor
Centre Francois Baclesse
Phase
Not applicable
Overall status
Completed
Start date
April 3, 2024
Completion date
August 16, 2025
Enrollment
192 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adult patients initiating injectable anticancer